Navigation Links
St. Francis Hospital to be Part of Major Nationwide Study Using a Catheter-Based Aortic Valve Replacement
Date:1/11/2011

ROSLYN, N.Y., Jan. 11, 2011 /PRNewswire/ -- Newell Robinson, M.D., Chairman of the Department of Cardiothoracic & Vascular Surgery; George Petrossian, M.D., Director of Interventional Cardiovascular Procedures; Andrew Berke, M.D., interventional cardiologist; and Roberto Colangelo, M.D., cardiothoracic surgeon at St. Francis Hospital, The Heart Center® are part of the medical team that is testing a device that may offer new hope for patients with symptomatic, severe aortic stenosis.

St. Francis Hospital has been selected as one of 40 centers nationwide to assess the Medtronic CoreValve system for transcatheter aortic valve implantation (TAVI), which has recently received conditional approval from the FDA for clinical trials.  St. Francis is one of the first hospitals in the U.S. to be activated as a site, and cardiologists have begun the process of implanting it in patients who are at high risk, or are ineligible, for open heart surgery.

Approximately 300,000 people worldwide (100,000 in the U.S.) have been diagnosed with the condition, which prevents the valve from opening completely, thereby preventing healthy blood flow from the aorta to the rest of the body.  But about one third of these patients are deemed at too high a risk for open heart surgery,(i) the only therapy with significant clinical effect that is currently available in the United States.  Although the CoreValve system has been implanted in 12,000 patients worldwide, it has not been available to patients in the U.S. until now.

The new valve replacement procedure channels a tube called a catheter with a prosthetic valve through the femoral artery to reach the heart.  The CoreValve System is designed with self-expandable technology, deploying the new valve inside the diseased aortic valve without open-heart surgery or surgical removal of the native valve.

"This is the most revolutionary device I've seen in my more than 20 years of being a cardiologist.  Nothing that I have witnessed in the past can change the way we practice interventional cardiology in such a dramatic way," says Dr. Petrossian.

"CoreValve has been used extensively in Europe.  The expectation is that we will be able to treat patients that otherwise we could not have treated, and be able to improve their lifestyles so they can stay out of heart failure for a longer period of time even though they aren't a candidate for surgery," says Dr. Robinson.

The Hospital's Chairman of Cardiology, Richard Shlofmitz, M.D., was instrumental in bringing the study to St. Francis.  He sees a time in the future when the benefits of these innovative devices will be available to a broader segment of patients who are not a high risk for surgery.  "This new approach is likely to have the same impact on the treatment of valvular disease as stenting did on coronary artery disease."

For more information about the study, log on to www.clinicaltrials.gov.  For more information about enrolling in the study, call (516) 562-6790, or visit www.stfrancisheartcenter.com.

Contact: Paul Barry, 516-705-6657, paul.barry@chsli.org

Rosemary Gomez, 516-705-6656, rosemary.gomez@chsli.org

(i) Iung B, Cachier A, Baron G, et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J. 2003;26:2714-2720.


'/>"/>
SOURCE St. Francis Hospital
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
2. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
3. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
4. St. Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients Heart Structures
5. Marc J. Fagel of the U.S. Securities and Exchange Commission to Discuss SEC Enforcement at CBIs Biotech/Pharma Finance and Accounting Forum in San Francisco
6. Takeda San Francisco, Inc. Appoints Michael Buckley, Ph.D. Vice President of Process Sciences
7. Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Societys Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
8. Lumenis Introduces Advanced Retinal Laser Delivery Technology at the 2009 American Academy of Ophthalmology Annual Meeting in San Francisco, California, USA
9. Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco
10. Dehaier Medical Systems to Present to Investors at Global Hunter Securities 2010 China Investor Conference in San Francisco
11. BIO Ventures for Global Health Opens San Francisco Office; Hires New Senior Staff
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Australien, 24. Februar 2017 ITL ... Unternehmen des Gesundheitsbereiches, ist erfreut, für das zum ... dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. ... Aktualisierung zum Wachstum" finden Sie hier . ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... 23, 2017  This report analyzes the worldwide markets ... Products: Intermediates, Analytical, and Others. The ... Pharmaceuticals, and Agrochemicals. The report provides separate comprehensive analytics ... Europe , and Rest of World. Annual ... through 2022. Also, a six-year historic analysis is provided ...
(Date:2/24/2017)... 2017 Medivir AB (Nasdaq Stockholm: ... new Board of Directors that will be submitted to ... comprises representatives of the company,s three largest shareholders at ... have accepted a seat on the Nomination Committee, and ... 2016-2017 Nomination Committee was as follows:  ...
Breaking Medicine Technology:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... provides business development, education, networking and recognition opportunities as well as advocacy for ... Works in Holmdel, NJ on February 23. The Council's Innovation Forecast event ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... and hearing disabilities, it is so critically important that we all are aware ... That is why Mediaplanet is proud to announce the launch of its newest ...
(Date:2/24/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... Yisrayl makes an astounding statement when he says that the entire Bible was written ... the current times so plainly that anyone should be able to see the time ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... into the Senior International Elite division on February 12th. Ms. Esparza qualified ... at the elite qualifier competition held in Las Vegas, Nevada. Frida is one ...
(Date:2/23/2017)... Miami, FL (PRWEB) , ... February 23, 2017 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – will return to the La Gorce Country Club in Miami Beach ...
Breaking Medicine News(10 mins):